Matinas BioPharma Holdings Stock Price, News & Analysis (NYSEAMERICAN:MTNB)

$1.19 0.02 (1.71 %)
(As of 11/18/2017 04:00 PM ET)
Previous Close$1.19
Today's Range$1.15 - $1.20
52-Week Range$1.01 - $3.99
Volume66,584 shs
Average Volume146,157 shs
Market Capitalization$112.5 million
P/E RatioN/A
Dividend YieldN/A

About Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

Matinas BioPharma Holdings logoMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.

Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: N/A
  • CUSIP: N/A
  • Web:
  • Trailing EPS: ($0.44)
  • Net Margins: -8,834.65%
  • Return on Equity: -143.22%
  • Return on Assets: -79.91%
  • Outstanding Shares: 92,950,000

Frequently Asked Questions for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

What is Matinas BioPharma Holdings' stock symbol?

Matinas BioPharma Holdings trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

How were Matinas BioPharma Holdings' earnings last quarter?

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) released its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.01. The business earned $0.05 million during the quarter, compared to the consensus estimate of $0.05 million. Matinas BioPharma Holdings had a negative return on equity of 143.22% and a negative net margin of 8,834.65%. View Matinas BioPharma Holdings' Earnings History.

Where is Matinas BioPharma Holdings' stock going? Where will Matinas BioPharma Holdings' stock price be in 2017?

3 equities research analysts have issued 12 month target prices for Matinas BioPharma Holdings' stock. Their forecasts range from $6.00 to $9.00. On average, they anticipate Matinas BioPharma Holdings' share price to reach $7.67 in the next twelve months. View Analyst Ratings for Matinas BioPharma Holdings.

What are Wall Street analysts saying about Matinas BioPharma Holdings stock?

Here are some recent quotes from research analysts about Matinas BioPharma Holdings stock:

  • 1. Maxim Group analysts commented, "Summary Matinas stock is down sharply today on news that MAT2203’s efficacy in VVC (vulvovaginal candidiasis) fell well below expectations both internal and external, but wait a second…Was it ever supposed to compare?." (6/26/2017)
  • 2. Aegis analysts commented, "Matinas reported the results of the Phase I study testing safety, tolerability and pharmacokinetics of MAT2501, its cochleated version of amikacin. This announcement meets the endpoints and time frame we had expected. Separately, we have received inquiries regarding comments posted to a financial website to which we attribute the recent volatility in the stock. We believe these comments are based on incorrect information, and reiterate our Buy rating on the stock." (3/28/2017)

Are investors shorting Matinas BioPharma Holdings?

Matinas BioPharma Holdings saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,055,677 shares, an increase of 1.2% from the October 13th total of 2,032,088 shares. Based on an average daily trading volume, of 187,156 shares, the days-to-cover ratio is currently 11.0 days. Currently, 2.9% of the shares of the stock are short sold.

Who are some of Matinas BioPharma Holdings' key competitors?

Who are Matinas BioPharma Holdings' key executives?

Matinas BioPharma Holdings' management team includes the folowing people:

  • Jerome D. Jabbour J.D., President (Age 42)
  • Roelof Rongen, Chief Executive Officer, Director (Age 51)
  • Gary Gaglione CPA, Vice President of Finance and Accounting and Acting Chief Financial Officer (Age 64)
  • Douglas F. Kling, Senior Vice President - Clinical Development (Age 43)
  • Abdel A. Fawzy Ph.D., Executive Vice President for Pharmaceutical and Supply Chain Development (Age 66)
  • Dominick M. Dipaolo, Senior Vice President - Quality and Regulatory Compliance (Age 41)
  • Raphael J. Mannino Ph.D., Chief Scientific Officer (Age 70)
  • Herbert J. Conrad, Chairman of the Board (Age 84)
  • Eric J. Ende M.D., Director (Age 48)
  • Adam K. Stern, Director (Age 53)

Who owns Matinas BioPharma Holdings stock?

Matinas BioPharma Holdings' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Yellowstone Partners LLC (0.16%). Company insiders that own Matinas BioPharma Holdings stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma Holdings.

Who bought Matinas BioPharma Holdings stock? Who is buying Matinas BioPharma Holdings stock?

Matinas BioPharma Holdings' stock was acquired by a variety of institutional investors in the last quarter, including Yellowstone Partners LLC. Company insiders that have bought Matinas BioPharma Holdings stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma Holdings.

How do I buy Matinas BioPharma Holdings stock?

Shares of Matinas BioPharma Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Matinas BioPharma Holdings' stock price today?

One share of Matinas BioPharma Holdings stock can currently be purchased for approximately $1.19.

How big of a company is Matinas BioPharma Holdings?

Matinas BioPharma Holdings has a market capitalization of $112.5 million.

How can I contact Matinas BioPharma Holdings?

Matinas BioPharma Holdings' mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.

MarketBeat Community Rating for Matinas BioPharma Holdings (NYSEAMERICAN MTNB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  110
MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.67

Consensus Price Target History for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

Price Target History for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

Analysts' Ratings History for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

DateFirmActionRatingPrice TargetDetails
8/10/2017Roth CapitalSet Price TargetBuy$9.00View Rating Details
8/8/2017Maxim GroupSet Price TargetBuy$6.00View Rating Details
3/28/2017AegisReiterated RatingBuy -> Positive$8.00View Rating Details
(Data available from 11/19/2015 forward)


Earnings History and Estimates Chart for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

Earnings by Quarter for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

Earnings History by Quarter for Matinas BioPharma Holdings (NYSEAMERICAN MTNB)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017Q3 2017($0.05)($0.04)$0.05 million$0.05 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.05)($0.04)$0.02 million$0.05 millionViewListenView Earnings Details
5/16/2017Q1 2017($0.04)($0.25)$0.02 millionViewN/AView Earnings Details
4/3/2017Q4 2016($0.08)($0.03)ViewListenView Earnings Details
11/10/2015Q3 2016($0.03)($0.11)$0.10 million$0.06 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.05)($0.04)$0.10 million$0.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

No earnings estimates for this company have been tracked by


Dividend History for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Matinas BioPharma Holdings (NYSEAMERICAN MTNB)

Insider Trades by Quarter for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

Insider Trades by Quarter for Matinas BioPharma Holdings (NYSEAMERICAN MTNB)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/8/2017Adam K SternDirectorBuy100,000$1.38$138,000.00View SEC Filing  
9/8/2017Roelof RongenCEOBuy5,000$1.36$6,800.00View SEC Filing  
9/7/2017James S ScibettaDirectorBuy5,000$1.29$6,450.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Matinas BioPharma Holdings (NYSEAMERICAN MTNB)


Social Media

Social activity is not available for this stock.



Matinas BioPharma Holdings (NYSEAMERICAN MTNB) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.